Analyst: Expanding Money Supply Could Push Bitcoin Above $132,000 by Year-End
According to a report by Jinse Finance, the U.S. federal debt has reached a record $37 trillion. Rising deficits and the potential growth in money supply could support Bitcoin prices climbing to $132,000 by the end of the year. Analysts note that the ever-expanding deficit may eventually prompt a shift toward more accommodative monetary policies, including quantitative easing. Quantitative easing refers to central banks purchasing large amounts of bonds to inject liquidity into the financial system. Bitcoin advocates believe that the increasing money supply and mounting concerns over inflation may lead to a renewed appreciation of Bitcoin’s monetary scarcity, potentially driving the world’s first cryptocurrency to new all-time highs. Jamie Coutts, Chief Crypto Analyst at Real Vision, estimates that, based on its correlation with BTC, the growing money supply could push Bitcoin’s price above $132,000 by the end of 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
